18.06.2015 • NewsAllerganDede Willams

Merged Allergan Buys Kythera

The newly merged Allergan – as generics drugmaker Actavis rebranded itself following the takeover of Allergan – has announced it is acquiring Kythera Biopharmaceuticals for $2.1 billion in cash and shares.

Allergan is offering Kythera shareholders $75 per share, 23.5% above the share price in trading on Jun. 16.

Kythera is interesting to the Botox manufacturer, which bills itself as a leader in "facial esthetics,” in particular because of its new injectable drug Kybella, which won FDA approval in April of this year.

Kybella will be used to reduce double chins, and Kythera is also working on developing a product to prevent male-pattern baldness.

Allergan said double chins are a “common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance,” adding that its customers, such as physicians and clinics, "are looking to offer their patients new options."
 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.